The role of alternative regimens in the management of tuberculosis in transplant recipients: From past challenges to future opportunities
This article relates to:
-
Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report
- Marcelo Victor Radisic,
- Natalia Rosana Pujato,
- Pablo Martin Bravo,
- Roxana Constanza del Grosso,
- Martin Hunter,
- Santiago Beltramino,
- Laura Linares González,
- María Lucía Cornet,
- Maria del Carmen Rial,
- Rosa Livia Franzini,
- Ana C. Dotta,
- Luis Roberto León,
- Javier Walther,
- Pablo Daniel Uva,
- Gustavo Werber,
- Volume 24Issue 6Transplant Infectious Disease
- First Published online: December 14, 2022
Antonio Doblas
Hospital Universitario Reina Sofia—Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
Search for more papers by this authorCorresponding Author
Julian Torre-Cisneros
Hospital Universitario Reina Sofia—Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
Universidad de Córdoba, Córdoba, Spain
Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Correspondence
Julian Torre-Cisneros, Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Avda. Menéndez Pidal s/n, 14004-Córdoba, Spain.
Email: [email protected]
Search for more papers by this authorAntonio Doblas
Hospital Universitario Reina Sofia—Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
Search for more papers by this authorCorresponding Author
Julian Torre-Cisneros
Hospital Universitario Reina Sofia—Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
Universidad de Córdoba, Córdoba, Spain
Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Correspondence
Julian Torre-Cisneros, Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Avda. Menéndez Pidal s/n, 14004-Córdoba, Spain.
Email: [email protected]
Search for more papers by this authorCONFLICT OF INTEREST
We have not conflicts of interest
REFERENCES
- 1Torre-Cisneros J, Doblas A, Aguado JM, et al. Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009; 48: 1657-1665.
- 2Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009; 48: 1276-1284.
- 3Doblas A, Torre-Cisneros J. The current state of tuberculosis in solid organ transplantation: three principles for optimal management. Am J Transplant. 2011; 11: 1769-1770.
- 4Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015; 60: 1642-1649.
- 5Aguado JM, Herrero JA, Gavaldá J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation. 1997; 63: 1278-1286.
- 6Radisic MV, Pujato NR, Martin P, et at. Tuberculosis treatment without rifampin in kidney/kidney pancreas transplantation: a case series report. Transpl Infect Dis. 2022; 24(6):e13949.
- 7Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2019; 25: 936-943.
- 8Babar ZU, Nasim A, Kumar S, et al. A case series of multidrug-resistant tuberculosis in renal transplant recipients: challenges in management from a TB endemic country. Transpl Infect Dis. 2021; 23:e13659.
- 9Wang X, Mallikaarjun S, Gibiansky E. Population pharmacokinetic analysis of delamanid in patients with pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2020; 65: e01202-e01220.
- 10Gils T, Lynen L, de Jong BC, et al. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect. 2022; 28: 31-42.
